BeiGene, Ltd.

NasdaqGS:BGNE 주식 보고서

시가총액: US$20.2b

BeiGene 관리

관리 기준 확인 2/4

BeiGene CEO는 John Oyler, Jan2010 에 임명되었습니다 의 임기는 14.83 년입니다. 총 연간 보상은 CN¥ 134.33M, 4.6% 로 구성됩니다. 4.6% 급여 및 95.4% 보너스(회사 주식 및 옵션 포함). 는 $ 711.85M 가치에 해당하는 회사 주식의 3.52% 직접 소유합니다. 711.85M. 경영진과 이사회의 평균 재임 기간은 각각 3.2 년과 4.3 년입니다.

주요 정보

John Oyler

최고 경영자

CN¥134.3m

총 보상

CEO 급여 비율4.6%
CEO 임기14.8yrs
CEO 소유권3.5%
경영진 평균 재임 기간3.2yrs
이사회 평균 재임 기간4.3yrs

최근 관리 업데이트

Recent updates

BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion

Nov 06

BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat

Aug 22

Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts

Aug 14
Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts

BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth

Aug 09
BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

Jun 21

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

May 30
We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

Apr 21
Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

Mar 08

BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Jan 31
BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

Oct 16
Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?

Jul 11
Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?

Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

Jun 19
Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)

Apr 17
Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)

A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)

Mar 24
A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)

CEO 보상 분석

John Oyler 의 보수는 BeiGene 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-CN¥6b

Jun 30 2024n/an/a

-CN¥4b

Mar 31 2024n/an/a

-CN¥6b

Dec 31 2023CN¥134mCN¥6m

-CN¥6b

Sep 30 2023n/an/a

-CN¥7b

Jun 30 2023n/an/a

-CN¥13b

Mar 31 2023n/an/a

-CN¥13b

Dec 31 2022CN¥124mCN¥6m

-CN¥14b

Sep 30 2022n/an/a

-CN¥15b

Jun 30 2022n/an/a

-CN¥14b

Mar 31 2022n/an/a

-CN¥12b

Dec 31 2021CN¥106mCN¥5m

-CN¥9b

Sep 30 2021n/an/a

-CN¥9b

Jun 30 2021n/an/a

-CN¥9b

Mar 31 2021n/an/a

-CN¥8b

Dec 31 2020CN¥94mCN¥5m

-CN¥11b

Sep 30 2020n/an/a

-CN¥10b

Jun 30 2020n/an/a

-CN¥10b

Mar 31 2020n/an/a

-CN¥8b

Dec 31 2019CN¥88mCN¥5m

-CN¥7b

Sep 30 2019n/an/a

-CN¥6b

Jun 30 2019n/an/a

-CN¥5b

Mar 31 2019n/an/a

-CN¥5b

Dec 31 2018CN¥192mCN¥4m

-CN¥5b

Sep 30 2018n/an/a

-CN¥3b

Jun 30 2018n/an/a

-CN¥2b

Mar 31 2018n/an/a

-CN¥923m

Dec 31 2017CN¥67mCN¥3m

-CN¥606m

보상 대 시장: John 의 총 보상 ($USD 18.56M )은 US 시장( $USD 12.66M ).

보상과 수익: 회사가 수익성이 없는 동안 John 의 보상이 증가했습니다.

CEO

John Oyler (56 yo)

14.8yrs

테뉴어

CN¥134,331,046

보상

Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009....

리더십 팀

이름위치테뉴어보상소유권
John Oyler
Co-Founder14.8yrsCN¥134.33m3.52%
$ 711.8m
Xiaobin Wu
President & COO6.5yrsCN¥78.08m0.056%
$ 11.2m
Xiaodong Wang
Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder14.8yrsCN¥31.35m0.83%
$ 167.0m
Chan Lee
General Counsel & Senior VP2.3yrsCN¥28.74m0.017%
$ 3.5m
Wang Lai
Global Head of R&Dno dataCN¥51.93m0.13%
$ 26.1m
Aaron Rosenberg
CFO & Principal Financial Officerless than a year데이터 없음데이터 없음
Titus Ball
VP & Chief Accounting Officerless than a year데이터 없음0.0033%
$ 676.0k
Liza Heapes
Head of Investor Relationsno data데이터 없음데이터 없음
Yang Ji
Chief Compliance Officer1.1yrs데이터 없음데이터 없음
Yan Qi
Senior VP & Head of Public Affairs - Greater China3.8yrs데이터 없음데이터 없음
Mark Lanasa
Senior VP & Chief Medical Officer for Solid Tumors2.8yrs데이터 없음데이터 없음
Graham Hardiman
Global Head of Human Resources3.7yrs데이터 없음데이터 없음

3.2yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: BGNE 의 관리팀은 경험 ( 3.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
John Oyler
Co-Founder14.1yrsCN¥134.33m3.52%
$ 711.8m
Xiaodong Wang
Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder8.8yrsCN¥31.35m0.83%
$ 167.0m
Steven Young
Acting Head of Medicinal Chemistry & Member of Scientific Advisory Board3.6yrs데이터 없음데이터 없음
Michael Goller
Independent Non-Executive Director & Member of the Scientific Advisory Committee9.6yrsCN¥3.42m0.0034%
$ 684.1k
Corazon Sanders
Independent Non-Executive Director & Member of Scientific Advisory Committee4.3yrsCN¥3.56m0.0022%
$ 437.2k
Anthony Hooper
Independent Non-Executive Director4.8yrsCN¥3.64m0.0027%
$ 548.5k
Shalini Sharp
Directorless than a year데이터 없음데이터 없음
Alessandro Riva
Co-Chairman of Scientific Advisory Committee & Independent Non-Executive Director2.8yrsCN¥3.49m0.0021%
$ 433.2k
Olivier Brandicourt
Independent Non-Executive Directorless than a year데이터 없음0%
$ 0
Ranjeev Krishana
Independent Lead Director10.1yrsCN¥3.46m0.0034%
$ 684.1k
Margaret Han Dugan
Member of Scientific Advisory Board & Independent Non-Executive Director2.8yrsCN¥3.62m0.0021%
$ 433.2k

4.3yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: BGNE 의 이사회는 경험(평균 재직 기간 4.3 년)으로 간주됩니다.